[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-vaccines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-vaccines":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100568086","estimate-the-safety-and-effectiveness-of-adjuvanted-influenza-vaccine-among-asian-elderly-people-when-compared-to-non-adjuvanted-vaccines-100568086",false,"NCT06676644","Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines","A Comparative Study on the Immunogenicity and Safety of Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in the Elderly","influenza","Inclusion Criteria:\n\n* Adults aged 65 years or above\n* Presence of at least 1 chronic medical condition associated with increased risk of complicated influenza, including hypertension, chronic obstructive pulmonary disease (group A, B, E), asthma, congestive heart failure (ACC\u002FAHA stage A, B, C, D), coronary arterial disease, diabetes mellitus, chronic liver disease (Child-Pugh score A, B, C) or chronic kidney disease (stage 1\\~4), neuromuscular disorders, hematological or solid organ malignancies, recipient of hematopoietic stem cell transplantation or solid organ transplantation.\n\nExclusion Criteria:\n\n* Contraindications to influenza vaccination including history of severe adverse event after vaccination, such as anaphylaxis or Guillain-Barré Syndrome, or a severe bleeding tendency\n* Prior receipt of influenza vaccination during the current flu season.\n* Determination by the Principal Investigator (PI) that the participant is ineligible for enrollment based on clinical assessment.","ALL","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","To compare the immunogenicity, cellular immune response, and safety between adjuvanted (aIIV4) and non-adjuvanted (IIV4) seasonal influenza vaccines in the Taiwanese elderly population with chronic medical conditions.",[27,28],"Influenza Vaccines","Elderly",[15,30,31,32,33],"adjuvanted vaccine","immunogenicity","elderly","safety","RECRUITING","2026-02-22",{"date":37,"type":38},"2026-02-24","ACTUAL",{"date":40,"type":38},"2024-11-21",{"date":42,"type":21},"2027-12-31",{"name":44,"class":45},"National Taiwan University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100606581","phase-4-characterizing-the-human-airway-immune-response-to-flumist-vaccination-100606581","NCT07177417","Characterizing the Human Airway Immune Response to FluMist Vaccination","EVax-3: Human Upper and Lower Airway Mucosal Immune Response to FluMist Vaccination","EVax-3","Inclusion Criteria:\n\n* Healthy adults aged 18-40 years\n* Able to understand and give written informed consent\n* In stable health, as determined by medical history and targeted physical exam related to the history\n\nExclusion Criteria:\n\n* Prisoners\n* Anyone unable to provide full written informed consent\n* Pregnant women and nursing mothers or women who are planning to become pregnant during the study interval\n* Female subjects who are sexually active with male partners who are not actively on hormonal contraception or who do not have an IUD in place\n* Vaccination with a seasonal influenza vaccine or documented infection with seasonal influenza in the past 9 months\n* Receipt of any vaccine in the 28 days prior to the pre-vaccination study visit or planned receipt of any non-study vaccine before completion of study day 28 visit\n* Current smokers\n* BMI \\> 40\n* Individuals with an immunocompromising medical condition or who have received systemic immunosuppressants or immune-modifying drugs for \\> 14 days in total within 6 months prior to screening (for corticosteroids ≥ 10 mg\u002Fday of prednisone equivalent for \\> 14 days total) or is anticipating the need for immunosuppressive treatment at any time during participation in the study\n* Individuals who currently have symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator\n* History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the study\n* Have donated blood, blood products, or bone marrow within 30 days before study entry, plan to donate blood at any time during the duration of study participation, or plan to donate blood within 30 days after the last blood draw.\n* Current ongoing participation in a clinical trial evaluating an investigational agent unless the trial is in follow up only and the last dose of the investigational agent was taken \\>30 days or \\>5 half-lives prior to enrollment, whichever is greater.\n* Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial.\n\nFor participants willing to undergo bronchoscopy:\n\n* Any known chronic pulmonary, cardiovascular, neurologic or hematologic disorder that could, in the opinion of the physician bronchoscopist or the principal investigator, put the subject at unnecessary risk from the sedation and bronchoscopy procedures. These conditions may include, but are not limited to, the following: asthma, COPD, obstructive sleep apnea, pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, heart failure, previous myocardial infarction, hypertrophic cardiomyopathy, supraventricular tachycardia, paraplegia, quadriplegia, epilepsy, sickle cell disease, hemophilia, chronic anemia or active cancer.\n* Coagulopathy (primary or iatrogenic) which would contraindicate bronchoscopy for participants willing to have those procedures done. Any participant with an INR\\>1.4, PTT\\>40 or platelet count \\\u003C100,000 at study screening will not be eligible for bronchoscopy.\n* Evidence of significant pulmonary disease on the day of bronchoscopy, including pulse oximetry with oxygen saturation of 92% or less on room air, or infiltrate or pleural effusion on an upright PA and lateral chest x-ray performed on the day of bronchoscopy.\n* Allergy or contraindication to anesthesia for participants willing to have bronchoscopy done.",true,"18 Years","40 Years",{"count":59,"type":21},30,[61],"PHASE4","The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, volunteers between the ages of 18 and 40. The main purpose of the study is to measure the change in influenza vaccine-specific antibodies in the lower lungs and nose between vaccination and 14 days after participants receive the vaccine. All participants will be randomized to receive one of the two seasonal flu vaccines and will have blood and back of the nose swabs collected throughout the study. Some study participants will choose to undergo optional bronchoscopy procedures and will be included in the part of the study looking at lower lung immune responses.",[64,27,65],"Healthy Young Adults","Influenza Vaccine Response",[67,68,69,70,71,72],"FluMist","bronchoscopy","bronchoalveolar lavage","endobronchial biopsy","nasopharyngeal swab","inactivated influenza vaccine","2025-09-09",{"date":75,"type":38},"2025-09-17",{"date":73,"type":38},{"date":78,"type":21},"2028-11",{"name":80,"class":45},"Washington University School of Medicine",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":55,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":46},"100566622","vaccine-chatbot-for-improving-influenza-vaccination-uptake-100566622","NCT06657573","Vaccine Chatbot for Improving Influenza Vaccination Uptake","AI-enabled Vaccine Chatbot for Improving Influenza Vaccination Uptake in Children: a Cluster Randomized Trial","Inclusion Criteria:\n\n* Parents of the child visiting clinics.\n* Children aged between 6 and 59 months.\n* Children who have not received an influenza vaccine in both the current and previous flu seasons and have not yet made an appointment for an influenza vaccine.\n* Children who have no contraindications to receiving an influenza vaccine.\n* Provide informed consent and willing to participate throughout the study.\n\nExclusion Criteria:\n\n* Children vaccinated or appointed for influenza vaccination or with any contraindication to influenza vaccine.\n* Parents with mental disorders or visual\u002Freading impairments, and unable to cooperate with and undergo the intervention activities.\n* Unwilling to participate.","6 Months","59 Months",{"count":91,"type":21},1200,[24],"This study aims to assess the impact of a vaccine chatbot on improving influenza vaccination uptake among children aged between 6 and 59 months through a cluster randomized trial. Specifically, the main questions it seeks to answer are whether an AI-enabled vaccine chatbot will increase the uptake of influenza vaccine among children and their family members, and how it will influence parents' literacy and confidence towards influenza vaccine. It will explore the potential role of vaccine chatbot on vaccination services.\n\nA cluster randomization will be used to assign children to the intervention and control groups. Parents of children in the intervention group will be invited to use the influenza vaccine chatbot online through WeChat, the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the influenza vaccine and receive validated answers from the chatbot immediately. The intervention will last one and a half months, with invitations sent every ten days to reinforce the engagement. The control group will not use the chatbot during the intervention duration. After the intervention, the uptake, literacy, and confidence towards influenza vaccine will be compared between the intervention and control groups to evaluate the impact of vaccine chatbot.",[27],[96,97,98,99,100],"Influenza vaccine","vaccination","vaccine confidence","AI","Chatbot","NOT_YET_RECRUITING","2024-10-23",{"date":104,"type":38},"2024-10-24",{"date":106,"type":21},"2024-10-26",{"date":108,"type":21},"2025-03-31",{"name":110,"class":45},"Fudan University"]